HomeNDC LookupIngredientsMalathion › 51672-5294-04
Malathion .0005 g/mL Lotion — NDC 51672-5294-04 package photo

Malathion .0005 g/mL Lotion

by Sun Pharmaceutical Industries, Inc. · 1 BOTTLE in 1 CARTON (51672-5294-4) / 59 mL in 1 BOTTLE
NDC 51672-5294-04
🏷️ FDA NDC (as labeled) 51672-5294-4 billing pads the package segment with a zero
Rx only Generic On market Non-controlled
🗂️ Data synced Jul 24, 2026 · sources: openFDA · FDA label (DailyMed) · FDA Orange & Purple Book · First Databank · CMS NADAC, ASP, Medicare & Medicaid · RxNorm
📋 All sources & update times →

🆔 Identity & classification

FDA NDC (as labeled) 51672-5294-4
Product NDC 51672-5294
11-digit billing NDC 51672529404
NCPDP billing unit ML — per mL (volume)
UNII U5N7SU872W
UPC 0351672529444
Application # ANDA091559
SPL Set ID a0b1444b-f51b-44fd-8f23-2fff49b64bc0
Established class (EPC) Cholinesterase Inhibitor
Mechanism of action Cholinesterase Inhibitors
DEA schedule Non-controlled
Marketing category ANDA
Marketing status On market
FDA listing status Listed (active directory)
Marketing start 2014-01-31
Route TOPICAL
Dosage form LOTION
Substance MALATHION
GPI-14 90900030004120
GPI class Malathion
GCN Seq No 007657
GCN 31600
HICL code 003338
Ingredient (HICL) Malathion
HIC1 code Q
Therapeutic class — broad (HIC1) Ear/Eye/Nose/Rectum/Topical/Vagina/Other
HIC2 code Q5
Therapeutic class — intermediate (HIC2) Agents Acting Principally On The Skin
HIC3 code Q5R
Therapeutic class — specific (HIC3) Topical Antiparasitics
AHFS code 84:04.12.00
AHFS class Scabicides And Pediculicides
FDB label name MALATHION 0.5% LOTION
FDB brand name Malathion
Legend status F — Federal legend — prescription drug or device
Why two NDCs? The FDA registers this code as 51672-5294-4 — a 5-4-1 layout, and that's what's printed on the package and shown on DailyMed. For insurance claims, every NDC is standardized to a uniform 11-digit 5-4-2 format by adding a zero to the package segment → 51672-5294-04. Same drug, same package — only the format differs.
Where does this data come from?
Identifiers from the FDA openFDA NDC Directory and Structured Product Labeling; RxCUI from RxNorm (NLM); GPI from Medi-Span; GCN / HIC / AHFS / legend from First Databank.

🏭 Manufacturer & labeler

LabelerSun Pharmaceutical Industries, Inc.
Application holderSUVEN PHARMACEUTICALS LTD
FDA applicationANDA091559 (ANDA)
Labeler code51672
First marketedJan 2014
Product typeHuman Prescription Drug
Portfolio889 products on file
The labeler markets the product; the application holder owns the FDA approval. They’re often the same company but can differ (e.g. a repackager or an authorized generic). A mailing address / phone appears here when the manufacturer includes it in the product’s FDA label (not all do).
Where does this data come from?
Labeler, application holder and registered establishment from the FDA openFDA NDC Directory and Drugs@FDA; address/contact from the product’s FDA label.

🩺 Clinical

Label name MALATHION 0.5% LOTION Ingredient Malathion
📖 What it is MedlinePlus · NLM

Malathion lotion is used to treat head lice (small insects that attach themselves to the skin) in adults and children 6 years of age and older. It should not be used in infants and children younger than 2 years of age. Malathion is in a class of medications called pediculicides. It works by killing lice.

Read the full MedlinePlus article ↗
📗 Our plain-language guide HelloPharmacist
  • Always apply it to dry hair. Work the lotion through your hair and scalp until everything is thoroughly wet, and pay extra attention to the back of the head and neck where lice lik...
  • How exactly do I use malathion lotion — do I put it on wet or dry hair?
  • The lotion is highly flammable — that's a real fire risk, not just a precaution. While your hair is wet with the lotion, you also need to stay away from lit cigarettes, open flames...
  • Why can't I use a hair dryer after applying the lotion?
📖 Read our full Malathion Topical guide →
Where does this data come from?
Plain-language summary from MedlinePlus (U.S. National Library of Medicine); supplement & herbal interactions and nutrient depletion data from the Natural Medicines database; our full guide is HelloPharmacist editorial content.

🧪 Inactive Ingredients / Excipients

Inactive ingredients, also called excipients, are components of the drug product other than the active ingredient. They may include fillers, dyes, coatings, preservatives, flavors, or other formulation ingredients.

💡 Tap an ingredient (hover on desktop) to see what it is and why it’s used.

  • UNII ND2M416302
    Isopropyl alcohol is a clear liquid solvent derived from petroleum. In medicines, it dissolves active ingredients and other components, helps the product flow smoothly, and aids in sterilization during manufacturing.
  • UNII 9MC3I34447
    A natural oil extracted from citrus peel, used as a flavoring agent and solvent to improve taste and help dissolve or distribute other ingredients in the medicine.
  • UNII 5EXL5H740Y
    A natural oil extracted from Scotch pine needles, used as a flavoring agent and fragrance component in medicines. It adds taste and aroma to improve how the medication tastes or smells.
  • UNII R53Q4ZWC99
    Terpineol is a fragrant alcohol derived from pine oil or other plant sources. It's used in medicines as a flavoring agent and to improve the taste or aroma of the product.

4 inactive ingredients listed in the exact product block matched to this NDC.

Where does this data come from?
Data sourced from official FDA Structured Product Labeling (SPL) via DailyMedingredient classCode="IACT" elements from the exact product block matched by this NDC. Label-section narrative from DailyMed / the openFDA label index is shown separately when available.

Inactive ingredient FAQ

Are inactive ingredients the same for every manufacturer?
No. Inactive ingredients can differ by manufacturer, dosage form, strength, and package / product version.
Why might an inactive ingredient be missing?
Some SPLs do not provide a complete structured inactive-ingredient list, and older or unusual labels may only include the information in narrative text.
Can inactive ingredients matter?
Yes. They can matter for allergies, intolerances, dyes, gluten / lactose concerns, preservatives, and formulation differences — but confirm with a pharmacist or the manufacturer when it’s clinically important.

💲 Pricing

A drug doesn't have one price. Each row is a different public payment system, and none is what you'd pay at the counter — that depends on your insurance. The ⓘ on each row explains what it measures.

Price systemPer mLPer package
Retail pharmacies payNADAC · weekly $3.201 $188.84 / 59 ml
Medicaid paysCMS SDUD · 12 mo $3.10 $182.65 / 59 ml
Medicare drug plans payPart D · Q2 2026 $3.11 $183.29 / 59 ml
NADAC price history (per mL) — tap or hover for the price & month
Jul 2022 Dec 2025 Apr 2026 Aug 2026 $3.713 $2.968
▼ Down 14% over the last 12 months.
Where does this data come from?
NADAC (National Average Drug Acquisition Cost) is the CMS weekly pharmacy-acquisition-cost survey — what pharmacies pay. ASP (Average Sales Price) is the CMS Medicare Part B drug-payment file, published quarterly. Medicaid pays is computed by us from CMS State Drug Utilization Data (total reimbursed ÷ units, trailing 12 months) — gross of rebates and inclusive of dispensing fees, so it reflects what Medicaid paid, not an acquisition cost. Medicare drug plans pay is the median negotiated point-of-sale unit cost across plans listing this NDC in the CMS quarterly Prescription Drug Plan pricing files, before rebates. The VA pays is the federal contract price (FSS, and the statutory Big 4 ceiling where listed) from the VA National Acquisition Center pharmaceutical price file. All are free public government data; each measures a different payer, so the figures are not directly comparable.

🔁 Therapeutic equivalents

ProductLabelerPackNADAC/unitTEStatusPrice vs. this
Malathion .0005 g/mLthis 51672-5294-04 Sun 1 bottle $3.201 Availability likely
Ovide .0005 g/mL 51672-5293-04 Sun 1 bottle FDA listed
About this product: this is a generic version of the medicine. FDA equivalence ratings are shown when available, and other versions are listed above, least expensive first.
Where does this data come from?
Equivalents are other NDCs of the same ingredient, form and route from the openFDA NDC Directory, ranked least-expensive-first by NADAC. Therapeutic-equivalence (AB) ratings come from the FDA Orange Book; biologics use the FDA Purple Book for biosimilar & interchangeable status.

Availability & generic status

🏛️
2014
On the market since
Jan 2014
📍
2026
Currently FDA-listed
12 years listed
🔓
·
Generic on the market
this product is a generic
This is a generic drug

This product is an FDA-approved generic. Other versions of the same drug are listed under Therapeutic equivalents, least expensive first.

Where does this data come from?
Patents and exclusivity from the FDA Orange Book (small-molecule drugs), refreshed from public FDA data. Generic launch timing is an estimate, not a guarantee.

🗺️ Medicaid utilization & spend

📍 This exact package only: Medicaid data is reported per full 11-digit NDC — labeler, product and pack size — so every number here is for 51672-5294-04, not the drug overall. Other pack sizes report separately.
💊 Pharmacy benefit only: These are Medicaid outpatient pharmacy claims, billed by NDC. They exclude the medical benefit — clinic- or hospital-administered drugs billed under HCPCS J-codes — so drugs used mostly that way (e.g. Avastin, Lucentis, Keytruda) can look low or missing here. That’s expected, not an error.
📅 Q1 2025 – Q4 2025 · 4 quarters of data
ⓘ The newest quarter is usually incomplete when first published; states restate recent quarters in later CMS releases, so the latest figures typically revise upward. State coverage-policy changes can also shift quarter-to-quarter totals.
Prescriptions last 4 qtrs
4.6K
Units reimbursed last 4 qtrs
296K
Gross reimbursed last 4 qtrs
$916.3K
Avg / prescription
$199.46
Avg / unit
$3.0958
Latest quarter Q4 2025
1.2KRx
Medicaid pays / mL
$3.0958
gross reimbursed
vs
NADAC / mL
$3.2007
acquisition cost
=
Spread
−$0.1049
-3% vs cost
What Medicaid paid per mL (before rebates; includes the pharmacy’s dispensing fee) compared with NADAC — the average price pharmacies pay to buy the drug. A positive spread means Medicaid reimbursed more than the purchase price, before manufacturer rebates.
Fee-for-service vs managed care
52% FFS 48% MCO
Fee-for-service · 2,383 Rx Managed care · 2,211 Rx
State Medicaid map
Alaska: no data reported AK Maine: no data reported ME Washington: no data reported WA Idaho: no data reported ID Montana: no data reported MT North Dakota: no data reported ND Minnesota: no data reported MN Wisconsin: no data reported WI Michigan: 18,231 units · 182 per 100k residents MI New York: 56,834 units · 290 per 100k residents NY Vermont: no data reported VT New Hampshire: 4,602 units · 328 per 100k residents NH Oregon: 5,782 units · 137 per 100k residents OR Nevada: 944 units · 29.6 per 100k residents NV Wyoming: no data reported WY South Dakota: 1,475 units · 161 per 100k residents SD Iowa: no data reported IA Illinois: no data reported IL Indiana: no data reported IN Ohio: 4,193 units · 35.6 per 100k residents OH Pennsylvania: 3,895 units · 30.1 per 100k residents PA New Jersey: 2,242 units · 24.1 per 100k residents NJ Massachusetts: 7,729 units · 110 per 100k residents MA California: 78,650 units · 202 per 100k residents CA Utah: no data reported UT Colorado: 5,841 units · 99.4 per 100k residents CO Nebraska: no data reported NE Missouri: no data reported MO Kentucky: 3,128 units · 69.1 per 100k residents KY West Virginia: no data reported WV Virginia: 18,939 units · 217 per 100k residents VA Maryland: 20,239 units · 327 per 100k residents MD Connecticut: no data reported CT Rhode Island: 4,543 units · 415 per 100k residents RI Arizona: 8,909 units · 120 per 100k residents AZ New Mexico: no data reported NM Kansas: no data reported KS Arkansas: no data reported AR Tennessee: no data reported TN North Carolina: 3,245 units · 29.9 per 100k residents NC South Carolina: 1,652 units · 30.7 per 100k residents SC Delaware: no data reported DE Oklahoma: no data reported OK Louisiana: no data reported LA Mississippi: no data reported MS Alabama: 12,336 units · 242 per 100k residents AL Georgia: 29,205 units · 265 per 100k residents GA D.C.: no data reported DC Hawaii: no data reported HI Texas: 2,715 units · 8.9 per 100k residents TX Florida: 649 units · 2.9 per 100k residents FL
Units reimbursed · per 100k residents
2.9415
gray = no data reported
Colors are per 100,000 residents, so big states don’t automatically dominate. Tap or hover a state for its actual totals.
Tap or hover a state
…for its Medicaid breakdown
🏆 Top states by units · per 100k residents
1 Rhode Island 415 /100k
2 New Hampshire 328 /100k
3 Maryland 327 /100k
4 New York 290 /100k
5 Georgia 265 /100k
6 Alabama 242 /100k
7 Virginia 217 /100k
8 California 202 /100k
National units — by quarter
💵 About the dollar figures: “reimbursed” is what Medicaid paid pharmacies before confidential manufacturer rebates, so the program’s real net cost is lower than these numbers. Fee-for-service and managed-care claims are combined unless split above. Source: CMS State Drug Utilization Data; per-100k rates use 2023 Census population estimates.

📊 Medicare Part D spend CMS · PART D · 2026 (Q1)

Medicare Part D (outpatient prescription) spending for Malathion — the program that covers self-administered drugs. 1 manufacturer.
⚠️ Drug-level data: CMS publishes Part D spending by drug, not by NDC — these figures combine every manufacturer, strength and package size sold under the name Malathion. That’s a different level of aggregation than the Medicaid card above, which is specific to this exact 11-digit NDC (pack size included), so the two aren’t directly comparable.
Period
Total Part D spend
$60.2K
Claims incl. refills
274
Beneficiaries
206
Spend / beneficiary
$292.46
Spend / claim
$219.88
Trend by period
💵 About the dollar figures: spending is what Part D plans paid before confidential manufacturer rebates, so the program’s real net cost is lower. A blank patient count means fewer than 11 people — CMS hides counts that small to protect privacy. Source: CMS Medicare Quarterly Part D Spending by Drug (data.cms.gov), updated quarterly.

🔬 Reported adverse events (FAERS)

Read carefully: FAERS reports are voluntary and unverified. Counts are not incidence, do not establish causation, are subject to reporting bias, and cannot be used to compare one drug to another. Shown for signal context only. Reports for Malathion — the ingredient across all brands.

Top reported reactions

Pain11
Alopecia9
Vomiting8
Drug Exposure During Pregnancy7
Dyspnoea7
Pregnancy With Injectable Contraceptive7
Thermal Burn7

Age at onset

Adolescent1
Adult7

Reporter sex

100 reports
Male · 13%
Female · 86%
Unknown · 1%

Serious outcomes

Hospitalization11
Disabling9
Death2
Reports over time (by year) — tap or hover for the count & year
2019 2021 2023 2026 5 0
Most recent year is provisional (FAERS lags ~3 months).
Where does this data come from?
Adverse-event reports from the FDA Adverse Event Reporting System (FAERS) via openFDA. FAERS reports are voluntary and unverified — counts are not incidence and don’t establish causation.

📦 Packaging — all sizes for this product

Package NDCDescription Marketing startStatus
51672-5294-04 You're viewing this 1 BOTTLE in 1 CARTON (51672-5294-4) / 59 mL in 1 BOTTLE 2014-01-31 Active

📄 Full prescribing information FDA SPL

The complete FDA label for this product — the official prescribing information, verbatim, section by section. Jump with a chip, search within the label, or expand everything.
🎯 Indications and Usage 23 words

INDICATIONS AND USAGE Malathion lotion is indicated for patients infected with Pediculus humanus capitis (head lice and their ova) of the scalp hair.

⏱️ Dosage and Administration 125 words

DOSAGE AND ADMINISTRATION Apply malathion lotion on DRY hair in amount just sufficient to thoroughly wet the hair and scalp. Pay particular attention to the back of the head and neck while applying malathion lotion. Wash hands after applying to scalp.

Allow hair to dry naturally - use no electric heat source, and allow hair to remain uncovered. After 8 to 12 hours, the hair should be shampooed. Rinse and use a fine - toothed (nit) comb to remove dead lice and eggs.

If lice are still present after 7 - 9 days, repeat with a second application of malathion lotion. Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.

Contraindications 45 words

CONTRAINDICATIONS Malathion lotion is contraindicated for neonates and infants because their scalps are more permeable and may have increased absorption of malathion. Malathion lotion should also not be used on individuals known to be sensitive to malathion or any of the ingredients in the vehicle.

⚠️ Warnings ~3 min read

WARNINGS Malathion lotion is flammable. The lotion and wet hair should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet.

Allow hair to dry naturally and to remain uncovered after application of malathion lotion. Malathion lotion should only be used on children under the direct supervision of an adult. If malathion lotion comes into contact with the eyes, flush immediately with water.

Consult a physician if eye irritation persists. If skin irritation occurs, discontinue use of product until irritation clears. Reapply the malathion lotion, and if irritation reoccurs, consult a physician.

Chemical burns including second-degree burns and stinging sensations may occur with the use of malathion lotion. General Keep out of reach of children. Close eyes tightly during product application.

If accidentally placed in the eye, flush immediately with water. Use only on scalp hair. Information to Patients Malathion lotion is flammable.

The lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet. The person applying malathion lotion should wash hands after application.

Allow hair to dry naturally and to remain uncovered after application of malathion lotion. Malathion lotion should only be used on children under the direct supervision of an adult. Children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet.

In case of accidental ingestion of malathion lotion by mouth, seek medical attention immediately. If you are pregnant or nursing, you should contact your physician before using malathion lotion. If malathion lotion comes into contact with the eyes, flush immediately with water.

Consult a physician if eye irritation persists or if visual changes occur. If skin irritation occurs, wash scalp and hair immediately. If the irritation clears, malathion lotion may be reapplied.

If irritation reoccurs, consult a physician. Burns and stinging sensations may occur when using malathion lotion. Apply malathion lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp.

Pay particular attention to the back of the head and neck when applying malathion lotion. Anyone applying malathion lotion should wash hands immediately after the application process is complete. Allow hair to dry naturally and to remain uncovered.

Shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing. Rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs. If lice are still present after 7 - 9 days, repeat with a second application of malathion lotion.

Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment. Laboratory Tests There are no special laboratory tests needed in order to use this medication.

Carcinogenesis Mutagenesis, and Impairment of Fertility Carcinogenesis, mutagenesis and impairment of fertility have not been studied with malathion lotion (0.5% pharmaceutical grade malathion). However, following long-term oral administration of technical grade malathion to rodents via dietary supplementation, increased incidences of hepatocellular neoplastic lesions were observed in B6C3F1 mice dosed for 18 months at malathion doses greater than 1500 mg/kg/day, and in female F344 rats dosed for 2 years at malathion doses greater than 400 mg/kg/day.

These tumors occurred only in association with severe hepatic toxicity and chronic suppression of acetylcholinesterase activity, or at doses causing excessive mortality. Based on body surface area, doses at which carcinogenic effects were observed in rodents following life-time exposures to malathion were approximately 14- to 26-fold grea…

🤒 Adverse Reactions 49 words

ADVERSE REACTIONS Malathion has been shown to be irritating to the skin and scalp. Other adverse reactions reported are chemical burns including second-degree burns. Accidental contact with the eyes can result in mild conjunctivitis. It is not known if malathion lotion has the potential to cause contact allergic sensitization.

🤰 Pregnancy 110 words

Pregnancy Pregnancy Category B There was no evidence of teratogenicity in studies in rats and rabbits at doses up to 900 mg/kg/day and 100 mg/kg/day malathion, respectively. A study in rats failed to show any gross fetal abnormalities attributable to feeding malathion up to 2,500 ppm (~ 200 mg/kg/day) in the diet during a three - generation evaluation period. These doses were approximately 40 to 180 times higher than the dose anticipated in a 60 kg adult (based on body surface area and assuming 100% bioavailability).

Because animal reproduction studies are not always predictive of human responses, this drug should be used (or handled) during pregnancy only if clearly needed.

🧒 Pediatric Use 24 words

Pediatric Use The safety and effectiveness of malathion lotion in children less than 6 years of age has not been established via well-controlled trials.

🆘 Overdosage 111 words

OVERDOSAGE Consideration should be given, as part of the treatment program, to the high concentration of isopropyl alcohol in the vehicle. Malathion, although a weaker cholinesterase inhibitor than some other organophosphates, may be expected to exhibit the same symptoms of cholinesterase depletion after accidental ingestion orally. If accidentally swallowed, vomiting should be induced promptly or the stomach lavaged with 5% sodium bicarbonate solution.

Severe respiratory distress is the major and most serious symptom of organophosphate poisoning requiring artificial respiration, and atropine may be needed to counteract the symptoms of cholinesterase depletion. Repeat analyses of serum and RBC cholinesterase may assist in establishing the diagnosis and formulating a long - range prognosis.

🧬 Clinical Pharmacology 96 words

CLINICAL PHARMACOLOGY Malathion is an organophosphate agent which acts as a pediculicide by inhibiting cholinesterase activity in vivo. Inadvertent transdermal absorption of malathion has occurred from its agricultural use. In such cases, acute toxicity was manifested by excessive cholinergic activity, i.e., increased sweating, salivary and gastric secretion, gastrointestinal and uterine motility, and bradycardia (see OVERDOSAGE ).

Because the potential for transdermal absorption of malathion from malathion lotion is not known at this time, strict adherence to the dosing instructions regarding its use in children, method of application, duration of exposure, and frequency of application is required.

📦 How Supplied / Storage and Handling 39 words

HOW SUPPLIED Malathion Lotion USP, 0.5%, is supplied in bottles of 2 fl. oz. (59 mL) NDC 51672-5294-4. Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Flammable. Keep away from heat and open flame.

📦 Storage and Handling 21 words

Store at 20° to 25°C (68° to 77°F) [see USP Controlled Room Temperature]. Flammable. Keep away from heat and open flame.

📋 Description 65 words

DESCRIPTION Malathion lotion contains 0.005 g of malathion per mL in a vehicle of isopropyl alcohol (78% v/v), terpineol, dipentene, and pine needle oil. The chemical name of malathion is (±) - [(dimethoxyphosphinothioyl) - thio] butanedioic acid diethyl ester. Malathion has a molecular weight of 330.36, represented by C 10 H 19 O 6 PS 2 , and has the following chemical structure: Chemical Structure

💬 Information for Patients ~1 min read

Information to Patients Malathion lotion is flammable. The lotion and hair wet with lotion should not be exposed to open flames or electric heat sources, including hair dryers and electric curlers. Do not smoke while applying lotion or while hair is wet.

The person applying malathion lotion should wash hands after application. Allow hair to dry naturally and to remain uncovered after application of malathion lotion. Malathion lotion should only be used on children under the direct supervision of an adult.

Children should be warned to stay away from lighted cigarettes, open flames, and electric heat sources while the hair is wet. In case of accidental ingestion of malathion lotion by mouth, seek medical attention immediately. If you are pregnant or nursing, you should contact your physician before using malathion lotion.

If malathion lotion comes into contact with the eyes, flush immediately with water. Consult a physician if eye irritation persists or if visual changes occur. If skin irritation occurs, wash scalp and hair immediately.

If the irritation clears, malathion lotion may be reapplied. If irritation reoccurs, consult a physician. Burns and stinging sensations may occur when using malathion lotion.

Apply malathion lotion on the scalp hair in an amount just sufficient to thoroughly wet hair and scalp. Pay particular attention to the back of the head and neck when applying malathion lotion. Anyone applying malathion lotion should wash hands immediately after the application process is complete.

Allow hair to dry naturally and to remain uncovered. Shampoo hair after 8 to 12 hours, again paying attention to the back of the head and neck while shampooing. Rinse hair and use a fine - toothed (nit) comb to remove dead lice and eggs.

If lice are still present after 7 - 9 days, repeat with a second application of malathion lotion. Further treatment is generally not necessary. Other family members should be evaluated by a physician to determine if infested, and if so, receive treatment.

Source: FDA Structured Product Labeling, mirrored from DailyMed / openFDA. Prefer the government’s original formatting? View this label on DailyMed ↗
For educational and professional reference only — not medical advice. Pricing reflects published NADAC and CMS ASP (free public data) and may differ from your acquisition cost; always verify before billing or dispensing.